Subunit-Selective PI3K Inhibition to Reverse Immunotherapy Resistance: Phase I/II Study of PI3Kβ and Pembrolizumab in Advanced Solid Tumors with PTEN Loss
Year: 2024
Type: preprint
Study design: Clinical Trial
Source: Research Square
Authors: Hussein Tawbi, Elizabeth Burton, Ecaterina Dumbrava, Ritu Bohat, Denai Milton, Rodabe Amaria, Jennifer McQuade, Isabella Claudia Glitza Oliva, Sumit Subudhi, Ana Aparicio, Paul Corn, Patrick Pilie, David Hong, Sapna Patel, Jordi Rodon, Timothy Yap, Xiaofang Liang, Chengtai Yu, Yitian Xu, Han Liang, Jack Lee, Khalida Wani, Jared Malke, Julie Simon, Courtney Hudgens, Patrick Hwu, Jennifer Wargo, Yitao Tang, Michael Tetzlaff, Alexander Lazar, Funda Meric-Bernstam, Michael Davies, Weiyi Peng
Institutions: The University of Texas MD Anderson Cancer Center, University of Houston, University of Colorado Cancer Center, Universitat Autònoma de Barcelona, Vall d'Hebron Hospital Universitari, Houston Methodist, The University of Texas Health Science Center at Houston, University of California, San Francisco
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4401734219